The pharmaceutical landscape shifted dramatically when the FDA approved the first gut microbiome drug in late 2022. This wasn't your typical chemical compound or synthetic molecule—it was something entirely different.
The landscape of rare disease treatment has undergone a remarkable transformation in 2025, with CRISPR therapy emerging as a beacon of hope for millions of patients worldwide suffering from orphan